Author(s):
|
Nadjm, B.; Dat, V.Q.; Campbell, J.I.; Dung, V.T.V.; Torre, A.; Tu, N.T.C.; Van, N.T.; Trinh, D.T.; Lan, N.P.; Trung, N.V.; Hang, N.T.; Hoi, L.T.; Baker, S.; Wolbers, M.; Chau, N.V.; Kinh, N. Van; Thwaites, G.E.; Doorn, H.R. van;
Wertheim, H.F.L.
|
Subject:
|
Radboudumc 4: lnfectious Diseases and Global Health RIHS: Radboud Institute for Health Sciences Tijdelijke code tbv inlezen publicaties Radboudumc - Alleen voor gebruik door Radboudumc |
Organization:
|
ITS Instituut Toegepaste Sociale Wetenschappen Medical Microbiology |
Abstract:
|
OBJECTIVES: We assessed the impact of MALDITOF-MS on the timeliness of optimal antimicrobial therapy through a parallel-arm randomised controlled trial in two hospitals in Vietnam. METHODS: We recruited patients with a pathogen (bacterial or fungal) cultured from a normally sterile sample. Samples were randomly assigned (1:1) to identification by MALDITOF-MS or conventional diagnostics. The primary outcome was the proportion on optimal antimicrobial therapy within 24h of positive culture, determined by a blinded independent review committee. Trial registered at ClinicalTrials.gov (NCT02306330). RESULTS: Among 1005 randomised patients, pathogens were isolated from 628 (326 intervention, 302 control), with 377 excluded as likely contaminants or discharged/died before positive culture. Most isolates were cultured from blood (421/628, 67.0%). The proportion receiving optimal antimicrobial therapy within 24h (the primary outcome) or 48h of growth was not significantly different between MALDITOF-MS and control arms (135/326, 41.4%vs 120/302, 39.7%; Adjusted Odds ration (AOR) 1.17, p=0.40 and 151/326, 46.3%vs 141/302, 46.7%; AOR 1.05 p=0.79, respectively). CONCLUSIONS: MALDITOF-MS, in the absence of an antimicrobial stewardship programme, did not improve the proportion on optimal antimicrobial therapy at 24 or 48h after first growth in a lower-middle income setting with high rates of antibiotic resistance.
|